Day: July 10, 2019

FDA Fast Tracks RRMM Drug for Potential Combination Therapy

This week, the United States Food and Drug Administration gave Kayropharm Therapeutics accelerated approval for its oral therapy drug selinexor (Xpovio), to be used with the corticosteroid dexamethasone as a combination therapy for adults with relapsed/refractory multiple myeloma (RRMM) and have run out of treatment options.  Relapsed/refractory multiple myeloma is